Suppr超能文献

侵袭性巨大泌乳素瘤:病例报告。

Aggressive giant prolactinoma: a case report.

机构信息

Endocrinology Unit, Medical Department, Sarawak General Hospital, Kuching Sarawak, Malaysia.

出版信息

J Med Case Rep. 2022 Apr 30;16(1):170. doi: 10.1186/s13256-022-03390-y.

Abstract

BACKGROUND

Managing treatment-resistant aggressive giant prolactinoma can be challenging, as the diagnosis is often complex, and treatment beyond dopamine agonists, surgery, and radiotherapy is limited.

CASE PRESENTATION

A 21-year-old Malay woman first presented to our hospital at the age of 16 years with 1-year history of reduced vision and 2 years of amenorrhea. Her baseline prolactin level was 255,894 µIU/mL with secondary hypogonadism, and pituitary magnetic resonance imaging revealed a giant prolactinoma (2.8 × 3.2 × 4.2 cm) with suprasellar extension and optic chiasmal compression. She was initially treated with cabergoline, and reductions in the prolactin level and tumor mass were achieved, leading to vision improvement and resumption of normal menstruation. However, she developed recurrent tumor growth and hyperprolactinemia, causing relapse of symptoms, and she needed surgery. Eventually, despite three tumor debulking surgeries and escalation of cabergoline doses up to 1 mg/day, her tumor progressed with aggressive characteristics. Following a multidisciplinary meeting, the patient is initiated on temozolomide therapy after considering the long-term side effects of radiotherapy in her case.

CONCLUSION

This case highlights the importance of early identification of treatment-resistant prolactinoma and the need for a multidisciplinary approach in managing aggressive prolactinoma in young patients, particularly regarding timely implementation of temozolomide therapy.

摘要

背景

治疗耐药性侵袭性大泌乳素瘤具有挑战性,因为诊断通常较为复杂,且除多巴胺激动剂、手术和放疗以外的治疗方法有限。

病例介绍

一名 21 岁的马来族女性,16 岁时首次就诊于我院,其病史为视力下降 1 年,闭经 2 年。她的基础催乳素水平为 255894µIU/mL,伴有继发性性腺功能减退,垂体磁共振成像显示巨大泌乳素瘤(2.8×3.2×4.2cm)伴鞍上扩展和视交叉压迫。她最初接受卡麦角林治疗,催乳素水平和肿瘤体积均有所下降,导致视力改善和月经恢复正常。然而,她出现肿瘤复发性生长和高催乳素血症,导致症状复发,需要手术治疗。最终,尽管进行了 3 次肿瘤切除术和卡麦角林剂量增加至 1mg/天,但她的肿瘤仍呈侵袭性进展。在多学科会议后,考虑到放疗在该病例中的长期副作用,为患者启用替莫唑胺治疗。

结论

本病例强调了早期识别耐药性泌乳素瘤的重要性,以及在年轻患者中管理侵袭性泌乳素瘤时需要多学科方法的重要性,特别是及时实施替莫唑胺治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b29f/9055719/dcbfd066b12b/13256_2022_3390_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验